Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ...
Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight DelveInsight's 'Acute Kidney Injury Pipeline ...
Cefazolin is noninferior to antistaphylococcal penicillins for methicillin-susceptible Staphylococcus aureus bacteremia and ...
Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...
MedPage Today on MSN
AI-triggered nephrology consult fails to prevent acute kidney injury in trial
Increases in serum creatinine similar to patients who received usual care ...
Highlights Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New ...
Five women in Rajasthan seeking help after alleged postpartum kidney failure have drawn attention to postpartum acute kidney ...
Morning Overview on MSN
A common blood-pressure pill mixed with a routine antibiotic can trigger kidney injury
Patients who take a calcium-channel blocker for high blood pressure and then receive a prescription for clarithromycin, one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results